PackGene is a world-leading CDMO company focus on providing end-to-end gene therapy solutions. Founded in 2014, PackGene now has offices in Houston (US) and Zurich (CH).

PackGene provides economical, reliable, and scalable AAV viral vector, plasmid DNA, and mRNA production to support programs from early-stage drug discovery, preclinical development to IND enabling and clinical studies. Our proprietary π-Alpha™ 293 AAV High-yield Platform uses uniquely designed RC plasmid in the triple-plasmid transfection system to increase AAV production by 3 to 8 fold.

PackGene’s mission is to accelerate gene therapy product development by providing an integrated one-stop solution including plasmid, viral vector, fill-finish and QC analytical services for the gene therapy industry.